UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000018426
Receipt number R000021332
Scientific Title The study of the efficacy of late intensification therapy and biochemical markers for pediatric Langerhans cell histiocytosis (JLSG-02)
Date of disclosure of the study information 2015/07/26
Last modified on 2016/06/07 17:22:12

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The study of the efficacy of late intensification therapy and biochemical markers for pediatric Langerhans cell histiocytosis (JLSG-02)

Acronym

JLSG-02

Scientific Title

The study of the efficacy of late intensification therapy and biochemical markers for pediatric Langerhans cell histiocytosis (JLSG-02)

Scientific Title:Acronym

JLSG-02

Region

Japan


Condition

Condition

Langerhans cell histiocytosis

Classification by specialty

Pediatrics

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

(a) To improve event-free survival (EFS) by intensifying the induction therapy regimen through increasing the PSL dose and prolonging maintenance therapy, thereby extending the total treatment duration to 54 weeks; (b) to improve survival of MS patients with progressive disease by adding CSA to the salvage regimen; and (c) to find out biochemical markers to reflect disease activity.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Phase II


Assessment

Primary outcomes

Event free survival at 5 years.

Key secondary outcomes

Overall survival at 5 years.


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Historical

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Multiple bone and Multi-system type: Induction A (6 weeks)Patients who had response to Induction A (GR / PR): Early maintenance A (24 weeks) and Late maintenance C (24 weeks)
Multiple bone and Multi-system type: Induction A (6 weeks)Patients who had no response to Induction A (NR): Induction B1 (6 weeks), Early maintenance B (24 weeks) and Late maintenance C (24 weeks)
Multiple bone and Multi-system type: Induction A (6 weeks)Patients who had no response to Induction A (PD): Induction B2 (6 weeks), Early maintenance B (24 weeks) and Late maintenance C (24 weeks)

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

0 years-old <=

Age-upper limit

18 years-old >=

Gender

Male and Female

Key inclusion criteria

1. Patients with histologicaly diagnosed LCH
2. Patients with Multiple bone or Multi-system type LCH

Key exclusion criteria

1. Patients with organ failure which make difficult to carry out the treatment
2. Patients receiving other treatment except steroids or surgical treatment for LCH
3. Informed consent is not obtained from patients and / or the guardians for treatment JLSG-02

Target sample size

150


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Akira Morimoto

Organization

Jichi Medical University

Division name

Pediatrics

Zip code


Address

3311-1 Yakushiji, Shimotsuke, Tochigi

TEL

0285-44-2111

Email

akira@jichi.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Akira Morimoto

Organization

Jichi Medical University

Division name

Pediatrics

Zip code


Address

3311-1 Yakushiji, Shimotsuke, Tochigi

TEL

0285-44-2111

Homepage URL

http://www.jlsg.jp/

Email

info@jlsg.jp


Sponsor or person

Institute

Japan LCH Study Group

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2015 Year 07 Month 26 Day


Related information

URL releasing protocol

http://www.jlsg.jp/english/JLSG-02protocol2.html

Publication of results

Published


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2001 Year 12 Month 01 Day

Date of IRB


Anticipated trial start date

2002 Year 01 Month 01 Day

Last follow-up date

2013 Year 12 Month 31 Day

Date of closure to data entry

2014 Year 03 Month 31 Day

Date trial data considered complete

2014 Year 09 Month 30 Day

Date analysis concluded

2015 Year 01 Month 31 Day


Other

Other related information



Management information

Registered date

2015 Year 07 Month 26 Day

Last modified on

2016 Year 06 Month 07 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000021332


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name